Premium
Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment
Author(s) -
Dyck Peter James,
O'Brien Peter C.,
Oviatt Karen F.,
Dinapoli Robert P.,
Daube Jasper R.,
Bartleson John D.,
Mokri Bahram,
Swift Thomas,
Low Phillip A.,
Windebank Anthony J.
Publication year - 1982
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410110205
Subject(s) - prednisone , polyradiculoneuropathy , medicine , nerve conduction , disease , pediatrics , guillain barre syndrome
Of 40 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 28 completed a controlled three‐month trial of prednisone. Prednisone was shown to cause a small but significant improvement over no treatment in scored neurological disability, some measures of computer‐assisted sensory detection threshold, graded muscle strength, and some attributes of nerve conduction. No subset of patients was more likely than another to be responsive to prednisone; those with a progressive course were as likely to be responsive as recurrent cases. This finding provides further justification for classifying progressive with recurrent cases as CIDP and demonstrates that prednisone treatment should not be withheld from patients with progressive disease.